The American Hospital Association (AHA) in a recent comment letter criticized a Food and Drug Administration (FDA) draft guidance on prescription point-of-care (POC) use blood glucose monitoring systems. The AHA said it was concerned the draft guidance would have serious unintended consequences for patients and hospitals, including placing patients at unnecessary risk. Nova Biomedical, a…

This content is for Paid Members only.
Login Register